Solid Restarts DMD Gene Therapy Trial, With Encouraging Interim Data To Back It Up

 
• By Jessica Merrill

The Phase I/II trial testing SGT-001 in patients with Duchenne muscular dystrophy resumed after FDA lifted a clinical hold on the trial; interim data from the first six patients were encouraging.

Railroad tracks seen from the back of an Adirondack train heading to Montreal, Canada, from New York, USA.
Solid's DMD gene therapy is back on track • Source: Shutterstock

More from Clinical Trials

More from R&D